Name: b-Cyclodextrin sulfobutyl ether sodium salt - USP
Price: Inquiry

- Overview
  - β-cyclodextrin sulfobutyl ether is an excipient compound incorporating a chemically modified cyclodextrin with a structure that optimises the solubility and stability of active pharmaceuticals and their properties. It is a highly water-soluble anionic cyclodextrin derivative. It can easily form non-covalent inclusion complexes with drug molecules and therefore reduce drug toxicity and haemolysis as well as control drug release rate. Its complexing properties also make it suitable for masking unpleasant odours and tastes of pharmaceutical products. It is used as an excipient in injection, oral, nasal and eye medication.
    
    Please contact us at for specific academic pricing.
- Properties
  - Categories
    
    Cyclodextrins
    
    Alternative Name
    
    SBE4-b-CyD;SBECD
    
    CAS Number
    
    182410-00-0
    
    Molecular Formula
    
    C70H119Na7O56S7
    
    Molecular Weight
    
    2,242.05 g/mol
    
    MDL Number
    
    MFCD12032209
    
    Note
    
    There is no hazardous surcharge associated with this product.
    There is no special packaging charge associated with this product.
    
    * For research use only. Not for human or veterinary use
- Reference
  - Szejtli (1998). Introduction and general overview of cyclodextrin chemistry, Chemical Reviews 98(5):1743-54.
    Tongiani et al. (2009). Sulfobutyl ether‐alkyl ether mixed cyclodextrin derivatives with enhanced inclusion ability. Journal of Pharmaceutical Sciences, 98(12):4769-80.
    Merzlikine et al. (2011). Development of machine learning models of β-cyclodextrin and sulfobutylether-β-cyclodextrin complexation free energies. International Journal of Pharmaceutics, 418(2):207-16.
    Irie et al. (1997). Pharmaceutical applications of cyclodextrins. III. Toxicological Issues and Safety Evaluation. Journal of Pharmaceutical Sciences, 86(2):147-62.
    Zia et al. (1997). Effect of alkyl chain length and degree of substitution on the complexation of sulfoalkyl ether β‐cyclodextrins with steroids. Journal of Pharmaceutical Sciences, 86(2):220-4.
    Tong et al. (2018). Preparation and characterization of Berberine Hydrochloride and Trimethoprim Chitosan/ SBE-β-CD microspheres. Journal of Drug Delivery and Technology, 48:300-10.
    Li et al. (2011). Novel sulfobutyl ether cyclodextrin gradient leads to highly active liposomal irinotecan formulation. Journal of Pharmacy and Pharmacology, 63(6):765-73.
    Cui et al (2011). Development of PEGylated liposomal vincristine using novel sulfobutyl ether cyclodextrin gradient: Is improved drug retention sufficient to surpass DSPE-PEG‐induced drug leakage. Journal of Pharmaceutical Sciences, 100(7):2835-48.
    Okimoto et al. (1999). Design and evaluation of an osmotic pump tablet (OPT) for chlorpromazine using (SBE) 7m-β-CD. Pharmaceutical Research, 16(4):549-54.
    Yildiz et al. (2017). Polymer-free electrospun nanofibers from sulfobutyl ether-β-cyclodextrin (SBE-βCD) inclusion complex with sulfisoxazole: Fast-dissolving and enhanced water-solubility of sulfisoxazole. International Journal of Pharmaceutics, 531(2):550-8.
    Järvinen et al. (1995). Sulfobutyl ether β-cyclodextrin (SBE-β-CD) in eyedrops improves the tolerability of a topically applied pilocarpine prodrug in rabbits. Journal of Ocular Pharmacology and Therapeutics, 11(2):95-106.

MSDS

Documents

Specification

We Also Recommend

AZD 1480

CC 292

CHIR 99021

Dasatinib monohydrate

Dasatinib Monohydrate

$180

Docetaxel trihydrate- Bio-X

Gemcitabine hydrochloride

Homoharringtonine

$306